Shifting from clinician-ordered to pathologist-initiated reflex testing for NSCLC biomarkers combines diagnosis and molecular analysis into one workflow. This operational change minimizes delays, increases testing rates, and optimizes the use of small biopsy samples, getting actionable results to oncologists faster.

Advanced biomarkers are no longer just research tools. Tools like Decipher provide results within a week from a shipped sample, and Artera's MMEI simply requires scanning a pathology slide. This practicality allows clinicians to personalize treatment intensification for high-risk patients in current clinical workflows, moving beyond purely clinical risk factors.

Genomics (DNA/RNA) only provides the 'sheet music' for cancer. Functional Precision Medicine acts as the orchestra, testing how live tumor cells respond to drugs in real time. AI serves as the conductor, optimizing the 'performance' for superior outcomes.

The personal genomics landscape is bifurcating. Direct-to-consumer companies offer broad, exploratory whole-genome sequencing for general interest, while clinician-mediated services provide targeted, actionable gene panels for specific medical conditions, creating distinct value propositions.

Clinicians increasingly perform Next-Generation Sequencing (NGS) on initial diagnostic tissue, even if results don't alter first-line treatment. This proactive approach identifies stable mutations like PIK3CA early, enabling long-term planning, such as optimizing a patient's metabolic health in anticipation of future targeted therapies.

The company's BioSeeker AI platform goes beyond discovery. After analyzing genomic data, it directly outputs the functional components for development: the 'guides' for their CRISPR therapeutics and the 'primers and probes' for their diagnostic tests, making AI a rapid creation tool.

The next wave of MedTech innovation won't just come from engineers. It will come from creating tools that allow surgeons and clinicians—those who see problems firsthand—to easily prototype and de-risk new device concepts, vastly expanding the market for innovation itself.

Building biologically relevant AI is not a one-off process. It demands a continuous "lab in the loop" system where wet lab experiments generate proprietary data to train models, whose outputs are then physically tested in the lab. This iterative feedback cycle constantly refines the model's predictive accuracy.

Sophia Genetics helped a hospital in India go from outsourcing tests to the US (with a 6-week delay) to performing them locally in under two weeks. This approach defines democratization not just as providing access, but as empowering local institutions to build their own knowledge and capabilities.